Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial

(MedPage Today) -- Combining lenvatinib (Lenvima) with an immune checkpoint inhibitor in the first-line setting for unresectable hepatocellular carcinoma (HCC) failed to significantly improve survival outcomes in an international phase III trial...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news